StockData

Generate Biomedicines, Inc. (GENB) stock

GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$10.37−0.01 (-0.10%)

Close on Nov 19, 2026Market cap $1.33BP/E –Yield –

Generate Biomedicines free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$57.01M–
Q2 FY2026Jun 30, 2026-$58.88M–
Q1 FY2026Mar 31, 2026-$84.17M–
Q3 FY2025Sep 30, 2025-$48.66M–
Q2 FY2025Jun 30, 2025-$48.91M–
Q1 FY2025Mar 31, 2025-$53.93M–

More Generate Biomedicines figures

See a number that looks wrong?